A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

Abroad (travel likely)RecruitingPHASE2

Conditions

Epidermolysis Bullosa Simplex

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Stanford University School of Medicine, Dermatology Department, Palo Alto, California, United States
Contact: Study coordinator (Thomas Buschbacher) · tbusch@stanford.edu · 650-313-0354
NU Dermatolgy CTU, Chicago, Illinois, United States
Contact: Study coordinator (NU Dermatolgy CTU) · NUderm-research@northwestern.edu · 312-227-6817

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Epidermolysis Bullosa Simplex · Ichthyosis · Genodermatosis

Abroad (travel likely)RecruitingPHASE2

Nice, France · Paris, France

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Epidermolysis Bullosa Simplex · Genodermatosis

Abroad (travel likely)RecruitingPHASE2

Nice, France · Paris, France